Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
Globe Newswire•15/10/2026•08:00 ET
0
Key Highlights
- ➤18 IgAN patients enrolled across three Phase 2 stage 1 dosing cohorts
- ➤Initial interim IgAN data expected by year-end 2026
- ➤FSGS cohort accelerated, with first patients anticipated to be dosed Q1 2027
- ➤Vensobafusp alfa targets both alternative and terminal complement pathways
- ➤Vensobafusp alfa remains investigational and unapproved for any indication
Expert Statements
Greg Keenan, M.D., Chief Medical Officer of Jasper Therapeutics
“Completing enrollment of the first IgAN cohort on schedule reflects both the high unmet need in this disease and strong execution by our clinical teams at Jasper and Kira.”
Greg Keenan, M.D., Chief Medical Officer of Jasper Therapeutics
“We are now expanding the study to include a cohort of patients with FSGS, a rare and severe kidney disease that often progresses to kidney failure.”
Greg Keenan, M.D., Chief Medical Officer of Jasper Therapeutics
“We believe vensobafusp alfa’s bifunctional ability to inhibit both the alternative and terminal complement pathways may provide the potential for differentiated onset and efficacy in complement driven diseases.”
Greg Keenan, M.D., Chief Medical Officer of Jasper Therapeutics
“We look forward to reporting initial data from the IgAN cohort by the end of this year and are actively working towards dosing the first patients with FSGS in first quarter 2027.”
(Initial Stage 1 data )(evaluating) (ven)(s)(obafusp)( alfa) (in )(IgAN)( expected )(by year-end)( 2026)
(Announces e)(xpansion )(cohort in patients with )(FSGS)(, with)( first patients anticipated to be dosed )(in )(first quarter 2027)
Get started
Create a free account to read the full story.